682804-05-3

Basic information

• Product Name: 3-AMINO-3-(3,4-DIFLUORO-PHENYL)-PROPIONIC ACID
• Synonyms: RARECHEM AK HW 0122;3-AMINO-3-(3,4-DIFLUORO-PHENYL)-PROPIONIC ACID
• CAS NO: 682804-05-3
• Molecular Formula: C9H9F2NO2
• Molecular Weight: 201.17
• Mol File: 682804-05-3.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-AMINO-3-(3,4-DIFLUORO-PHENYL)-PROPIONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-AMINO-3-(3,4-DIFLUORO-PHENYL)-PROPIONIC ACID(682804-05-3)
• EPA Substance Registry System: 3-AMINO-3-(3,4-DIFLUORO-PHENYL)-PROPIONIC ACID(682804-05-3)

Safety Data

• Hazardous Substances Data: 682804-05-3(Hazardous Substances Data)

Upstream product

• 34036-07-2 3,4 difluorobenzaldehyde 
• 141-82-2 malonic acid 
• 1393363-64-8 tert-butyl (3S,αR)-3-[N-benzyl-N-(α-methylbenzyl)amino]-3-(3',4'-difluorophenyl)propanoate 
• 447416-67-3 tert-butyl (3S,αR)-3-(3,4-difluorophenyl)-3-(N-benzyl-N-α-methyl-4-methoxybenzylamino)propanoate 
• 181517-78-2 tert-butyl (E)-3-(3',4'-difluorophenyl)prop-2-enoate 
• 181517-91-9 tert-butyl (S)-3-amino-3-(3',4'-difluorophenyl)propanoate 

Relevant articles and documents

1-PHENYLPYRROLIDIN-2-ONE DERIVATIVES AS PERK INHIBITORS

The invention is directed to substituted pyrrolidinone and imidazolidinone derivatives. Specifically, the invention is directed to compounds according to Formula I: (I) wherein R1, R2, R3, R4, R5, R6, R7, X and Y are as defined herein. The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases/injuries associated with activated unfolded protein response pathways, such as Alzheimer's disease, neuropathic pain, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, Parkinson's disease, diabetes, metabolic syndrome, metabolic disorders, Huntington's disease, Creutzfeldt- Jakob Disease, fatal familial insomnia, Gerstmann-Str?ussler-Scheinker syndrome, and related prion diseases, amyotrophic lateral sclerosis, progressive supranuclear palsy, myocardial infarction, cardiovascular disease, inflammation, organ fibrosis, chronic and acute diseases of the liver, fatty liver disease, liver steatosis, liver fibrosis, chronic and acute diseases of the lung, lung fibrosis, chronic and acute diseases of the kidney, kidney fibrosis, chronic traumatic encephalopathy (CTE), neurodegeneration, dementias, frontotemporal dementias, tauopathies, Pick's disease, Neimann-Pick's disease, amyloidosis, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the transportation of organs for transplantation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

3-(PYRIMIDINE-2-YL)IMIDAZO[1,2-A]PYRIDINES

The present application relates to novel 3-(pyrimidin-2-yl)imidazo[1,2-a]pyridines, to processes for preparation thereof, to the use thereof, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular disorders.

Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use

The present application relates to novel substituted imidazo[1,2-a]pyridine-3-carboxamides, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.